Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563368 | 1.00 | HRH3 (0.49) | HRH3LTA4HPARP1POLBHTR1D | |
| SCHEMBL27148278 | 0.98 | HRH3 (0.48) | HRH3LTA4HPARP1POLBHTR1D | |
| SCHEMBL27148280 | 0.98 | HRH3 (0.48) | HRH3LTA4HPARP1POLBHTR1D | |
| SCHEMBL23802786 | 0.83 | HRH3 (0.39) | HRH3POLBHTR1DMEN1KMT2A | |
| SCHEMBL23802852 | 0.83 | HRH3 (0.39) | HRH3POLBHTR1DMEN1KMT2A | |
| SCHEMBL4978859 | 0.82 | HRH3 (0.49) | HRH3LTA4HPARP1POLBMEN1 | |
| SCHEMBL1600792 | 0.82 | HRH3 (0.49) | HRH3LTA4HPARP1POLBREN | |
| SCHEMBL4749981 | 0.82 | HRH3 (0.49) | HRH3LTA4HPARP1POLBTDP1 | |
| SCHEMBL5504868 | 0.82 | HRH3 (0.49) | HRH3LTA4HPARP1POLB | |
| SCHEMBL1600790 | 0.82 | HRH3 (0.49) | HRH3LTA4HPARP1POLBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | HRH3 65/4885LTA4H 3505/4885PARP1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.